← All trials
NCT04562298
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 21, 2020
- Primary completion
- Nov 1, 2022
- Completion date
- Nov 1, 2024
- First posted
- Sep 24, 2020
- Last posted
- Dec 28, 2020
- Enrollment
- 34
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Fudan UniversityOverall official - principal investigator
- Anhui Medical UniversityCollaborator
- GenScriptCollaborator
- East Clinical Center of OncologyOverall official - principal investigator
- East Clinical Center of OncologyCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.